Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago.

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...

U.K.-based manufacturer of roof-integrated solar panels, Viridian Solar, has added two new monocrystalline PERC half-cut panels with power outputs of 335 and 340 W to its Clearline fusion range of ...

Viridian Solar, a UK-based manufacturer of building-integrated PV (BIPV) panels, has announced a new 445 W n-type TOPCon module. “The new panel utilizes the latest in solar cell technology to ...